EKEOMA OBASOHAN: Open Payments
NPI 1285216986 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$942 in 34 payments from 19 companies in 2025. Trend: 2023 $1,612 · 2024 $734 · 2025 $942
Food & beverage: $843Education: $99
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 5 | $139 |
| SEAGEN INC. | 1 | $99 |
| Adaptive Biotechnologies Corporation | 3 | $93 |
| Daiichi Sankyo Inc. | 3 | $81 |
| ABBVIE INC. | 3 | $80 |
| PFIZER INC. | 3 | $71 |
| Bard Peripheral Vascular, Inc. | 2 | $58 |
| Incyte Corporation | 3 | $58 |
| Kite Pharma, Inc. | 1 | $30 |
| AstraZeneca Pharmaceuticals LP | 1 | $30 |
Products named: SCEMBLIX, clonoSEQ, Vanflyta, ELREXFIO, Epkinly, Trek, JAKAFI, Yescarta.
Industry payments across TX — which companies pay providers there.
